Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients - Wikidata - awgldk - TriplyDB

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients

http://www.wikidata.org/entity/Q36040200

about

Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD Current perspectives on the immunopathogenesis of systemic sclerosis Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge Targeted Therapy in Systemic Sclerosis Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data.TGF-β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension.A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis TGF-β1 Is Present at High Levels in Wound Fluid from Breast Cancer Patients Immediately Post-Surgery, and Is Not Increased by Intraoperative Radiation Therapy (IORT)PDGF-BB Promotes Type I IFN-Dependent Vascular Alterations and Monocyte Recruitment in a Model of Dermal Fibrosis.Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis.Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions.Biomarkers in systemic sclerosis: Their potential to predict clinical courses.Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model.Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.Interstitial lung disease in systemic sclerosis: current and future treatment.Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.Therapeutic potential of NADPH oxidase 1/4 inhibitors.Autophagy: controlling cell fate in rheumatic diseases.Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.Emerging drugs and therapeutics for systemic sclerosis.Outside in: The matrix as a modifier of muscular dystrophy.Liver inflammation and fibrosis.Characterizing the "POAGome": A bioinformatics-driven approach to primary open-angle glaucoma.Targeting TGF-β Signaling for Therapeutic Gain.Protein Tyrosine Phosphatases in Systemic Sclerosis: Potential Pathogenic Players and Therapeutic Targets.Pathogenesis of systemic sclerosis-current concept and emerging treatments.An update on biomarker discovery and use in systemic sclerosis.Type I IFNs Regulate Inflammation, Vasculopathy, and Fibrosis in Chronic Cutaneous Graft-versus-Host Disease.Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90 Cell-penetrating peptides selectively targeting SMAD3 inhibit profibrotic TGF-β signaling.Sphingosine-1-Phosphate Receptor 5 Modulates Early-Stage Processes during Fibrogenesis in a Mouse Model of Systemic Sclerosis: A Pilot Study.Is macitentan not a treatment option for digital ulcers in systemic sclerosis?PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis The immunopathology of systemic sclerosis.A Unique TGFB1-Driven Genomic Program Links Astrocytosis, Low-Grade Inflammation and Partial Demyelination in Spinal Cord Periplaques from Progressive Multiple Sclerosis Patients.Recent advances in the treatment of skin involvement in systemic sclerosis.Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy.Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta.Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis.

P2860

Q26740540-06E1299D-0C42-4240-9970-F0D91439E572 Q26741264-E8D8A9B5-D62A-4B7D-9E0E-9D80FDC685B8 Q26782820-6B8A71EC-C782-48F0-86D9-F8E6AB75E158 Q28072943-7E1E5137-27B2-44CE-8BB6-5A7C5D4DE203 Q31020939-41DA8525-88E2-49A7-97CB-082AA982FB91 Q33766507-168EAC8B-BEE1-4581-8413-F4653257974E Q33923580-9C93CC18-0B55-4718-9B50-541354893276 Q36121570-9C7F784C-4950-45FC-B5DC-DD0C0610170E Q36130126-82E9823F-6A25-4953-932F-C2C75F8BEAEB Q37381549-1CCDB7DC-AF17-4C8D-9CFA-D79EC94AAA1A Q37395851-23F83D6A-3BD4-4A4C-BC1F-C05DEBBFC54C Q38649653-0034AEC0-3B32-45DF-9045-87957F94EE26 Q38701985-4126AC8B-7D47-45E8-A676-D14A58D2827B Q38721748-889BEB37-C1F5-412D-ADEA-1716DEF340A3 Q38771824-0654E907-F39C-4BD1-9005-5B9BFCB8F627 Q38773637-7D9DEFEE-76B3-4E47-B338-781158C8D173 Q38824987-56F429CC-3136-427F-9C98-4E6B883C1801 Q38858553-4B4FD951-530C-4D82-8C8D-A97874A0F5D1 Q38873681-5A8DE285-6E1A-4E96-8447-02936EAA590F Q38956376-1F089785-378D-4BFA-9C8F-672F3B6BABB7 Q38998611-26B08BEC-A99E-45E1-BF8A-3C08DDFDAEB9 Q39052032-B41CDF72-0C0E-41FB-98C0-E7F9A3F08FB1 Q39065620-C5D86E1B-E86F-4B53-AB5F-003E0520E532 Q39145730-C72AD5AB-0218-4BBB-9735-AB19D89E69AB Q39155151-0F35F431-1E4E-400E-8118-B359D9B8A89C Q39233347-08AD9E35-40F5-4AA8-8215-E37A5103AF30 Q39294794-40A2CD15-C062-4A23-9F74-857C39F8DB41 Q39450087-BEB1471F-4147-480C-B86D-BF9569F00C8E Q40659360-CE4A09E1-4D93-402C-BDF0-62DC36234DBE Q41630154-726DBD62-EDC0-4529-90DB-992F563E5122 Q41661766-86F8C7F1-95F3-48FE-AADA-A60B6E3CC8BF Q42369819-0AA3A218-CC7E-42FF-B605-9515F36F0E91 Q42370348-9B1D3AAB-14F2-4FFF-8BC0-8F56440A6ACA Q42652598-81B98CC7-7BFF-4C97-8152-5CAE805A2FA5 Q42971751-0FC644A3-4E26-4FF2-8345-990BC2EFACF4 Q46989452-0606433B-190B-4385-91D3-D40E4CBB025F Q47111024-BF311521-F80C-4D04-9DC1-73CA83CD76CA Q47133681-E4EADBF7-4C67-4D1C-B30C-2D8C3C7AE519 Q47610065-C6A8E6DC-AC38-4B86-A3E3-F726623269EC Q47651642-48A25FC1-1C70-433A-A854-A9BD9ED8E790

P2860

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients

http://www.wikidata.org/entity/Q36040200

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Fresolimumab treatment decreas ...... in systemic sclerosis patients

@ast

Fresolimumab treatment decreas ...... in systemic sclerosis patients

@en

type

label

Fresolimumab treatment decreas ...... in systemic sclerosis patients

@ast

Fresolimumab treatment decreas ...... in systemic sclerosis patients

@en

prefLabel

Fresolimumab treatment decreas ...... in systemic sclerosis patients

@ast

Fresolimumab treatment decreas ...... in systemic sclerosis patients

@en

P1433

Q36040200-C3E9331A-B8DD-41E7-9DC9-DEA7F3CE697F

P1476

Q36040200-A52FEFEE-FC9D-4AC7-B8C0-A36BB2CC05A9

P2093

Q36040200-16A3AF61-646D-4DD0-A070-B581110A78D3

Q36040200-191D96A8-08C5-4BFF-9E2A-83E9AD0B779B

Q36040200-27958ABF-6B9B-410C-BF68-9FDF530E4D88

Q36040200-31DBBD56-25FA-4BC6-A782-437BD086B4A8

Q36040200-4C1FC570-55D6-4761-AD79-C4975ED24759

Q36040200-56EF4B65-981B-403D-AFA7-DD33A3FF8783

Q36040200-58D5B8E8-E8E8-4150-AB23-8722F8ED0A81

Q36040200-6963460D-30CE-4574-BD21-D257CF61488C

Q36040200-9260A907-7C67-4767-B91C-86DBB3EE1428

Q36040200-C22F3939-9B0D-43A3-A91A-C72DB00E3E98

P2860

Q36040200-01F01C2A-597D-404E-BDCC-99F13219C44C

Q36040200-15C45798-D8D2-4033-8DB5-77DF7BB98D12

Q36040200-1B2FA127-912E-40C5-8538-7CB0342AF2E6

Q36040200-20BD3F76-F320-4584-A8A5-8B8A2205B2DA

Q36040200-259101FA-1175-4B74-8AA6-49E13ECCEEF7

Q36040200-28CB2B78-07F1-45C5-9018-CD12326C4EF3

Q36040200-2E759E45-3E69-4595-B243-C5D5DCDDC3FA

Q36040200-31ABD973-D1CD-4F04-89D1-3B21FC3C766A

Q36040200-3C461865-435C-41F8-B2BC-2FE6AE6DC9FF

Q36040200-4485D7B8-DFB6-47E8-B38F-FD6DEFDEAF0E

P304

Q36040200-174E0765-D6D9-4F65-8F69-32377E254F77

P31

Q36040200-F4ECF658-F7C8-4CCF-87E4-82F45C00C781

P356

Q36040200-798FD590-19A6-4E65-BCCA-A0FB2780A519

P407

Q36040200-F89C56D6-5AED-48D9-846C-9CA57A351345

P433

Q36040200-22B4E997-5B9E-4A08-9009-FC1DCBF47C60

P478

Q36040200-DAD6FE10-286D-4340-9A8F-88ACD26CA095

P50

Q36040200-A20E7C04-FEAB-412E-8B6D-2F8357ED7DF5

P577

Q36040200-868A6D73-E3F5-422C-AB4E-10DD4B7A3D83

P698

Q36040200-680E5037-22BB-48D7-B251-FA0C9913B754

P921

Q36040200-8879DED1-CC6E-46D9-BAE7-7BCE48B82B56

P932

Q36040200-8F2F15E8-291D-42C1-847F-C68678798DB8

P356

P1433

Journal of Clinical Investigation

P1476

Fresolimumab treatment decreas ...... in systemic sclerosis patients

@en

P2093

Allison Mathes

http://www.w3.org/2001/XMLSchema#string

Cristina M Padilla

http://www.w3.org/2001/XMLSchema#string

Janice Weinberg

http://www.w3.org/2001/XMLSchema#string

Jessica K Gordon

http://www.w3.org/2001/XMLSchema#string

Jessica Ziemek

http://www.w3.org/2001/XMLSchema#string

Lisa M Rice

http://www.w3.org/2001/XMLSchema#string

Michael L Whitfield

http://www.w3.org/2001/XMLSchema#string

Michael York

http://www.w3.org/2001/XMLSchema#string

Robert F Spiera

http://www.w3.org/2001/XMLSchema#string

Robert Lafyatis

http://www.w3.org/2001/XMLSchema#string

P2860

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

Cellular and molecular mechanisms of fibrosis

Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies

Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis

Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

Proteomic identification of ADAM12 as a regulator for TGF-β1-induced differentiation of human mesenchymal stem cells to smooth muscle cells

Open source clustering software

Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.

Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability.

P304

2795-2807

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI77958

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppina Farina

P577

2015-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26098215

http://www.w3.org/2001/XMLSchema#string

P921

P932

4563675

http://www.w3.org/2001/XMLSchema#string